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Resection of pancreas, in particular pancreaticoduodenectomy, is a complex procedure, commonly performed in appropriately
selected patients with benign and malignant disease of the pancreas and periampullary region. Despite signiﬁcant improvements
in the safety and eﬃcacy of pancreatic surgery, pancreaticoenteric anastomosis continues to be the “Achilles heel” of pancreati-
coduodenectomy, due to its association with a measurable risk of leakage or failure of healing, leading to pancreatic ﬁstula. The
morbidity rate after pancreaticoduodenectomy remains high in the range of 30% to 65%, although the mortality has signiﬁcantly
dropped to below 5%. Most of these complications are related to pancreatic ﬁstula, with serious complications of intra-abdominal
abscess, postoperative bleeding, and multiorgan failure. Several pharmacological and technical interventions have been suggested
to decrease the pancreatic ﬁstula rate, but the results have been controversial. This paper considers deﬁnition and classiﬁcation of
pancreatic ﬁstula, risk factors, and preventive approach and oﬀers management strategy when they do occur.
1.Introduction
Pancreaticoduodenectomy (PD) is one of the standard treat-
ments for various benign and malignant disease of the pan-
creatic head and periampullary region and distal pancreatec-
tomyforlesionsinthetailofpancreas.Recentlytheoperative
mortality after PD has signiﬁcantly declined to 3 to 5%,
while the incidence of postoperative morbidity remains high
ranging from 30% to 65% [1–8]. The single most signiﬁcant
causeofmorbidityandmortalityafterPDisthedevelopment
of pancreatic leak and ﬁstula. The leakage rate according
to recent reports varies from 0% to 25% depending on the
deﬁnition used [6–8]. Abdominal abscess and haemorrhage
are common sequelae of pancreatic anastomotic leakage
which have often been associated with a mortality rate of
40% or more [1–9]. Pancreatic ﬁstula (PF) hence has been
one of the major complications discouraging surgeons from
performing PD. Recent literature suggests that many factors
inﬂuence pancreatic leakage after PD, including sex, age,
jaundice, operative time, intraoperative blood loss, pan-
creaticojejunal anastomotic technique, texture of the rem-
nant pancreas, pancreatic duct size, use of somatostatin, and
surgeons experience [1–12]. Various strategies have been
employed to decrease the incidence of PF including pharma-
cological manipulations and reﬁnements and modiﬁcations
in surgical techniques, which are reviewed here.
2. Deﬁnitions
There is no universally accepted deﬁnition of PF. Most def-
initions of ﬁstula rely on amylase content from an intra-
abdominal drain as well as the daily volume of eﬄuent [2–
6] Table 1. Yet in the past decade there has been considerable
debate as to what threshold of amylase level deﬁnes a PF [2–
6]. In a recent study, Bassi et al. examined 26 deﬁnitions of
PF published between 1991 and 2000 [10]. Each deﬁnition
was arbitrarily assigned a score based on daily ﬂuid output
criteria and the timing of ﬁstula development (i.e., number
of days from onset and/or duration of ﬁstula). The results
revealed wide variations in the incidence of PF from 10%
to 29% depending upon the deﬁnition [10]. A special
study group, now known as the international study group
of PF (ISGPF) involving 37 notable pancreatic surgeons2 International Journal of Surgical Oncology
Table 1: The diﬀerent components of previously used deﬁnitions
of pancreatic ﬁstula prior to the new grading System by the inter-
national study group for pancreatic ﬁstula (ISGPF) (presented in
Table 2).
(i) Output >10mL/day of amylase rich ﬂuid on postoperative day
5o rf o r>5d a y s
(ii) Output >10mL/day of amylase rich ﬂuid on postoperative day
8o rf o r8d a y s
(iii) Output of >50mL/day of amylase rich ﬂuid after
postoperative day 11 or for more than 11 days
from 15 countries, came up with a deﬁnition of PF to
facilitate comparison of various studies [8]. The deﬁnition
was extended to standardizing of postoperative treatment.
Theessentialcomponentofananastomoticleakwasthehigh
amylase content (>3 times the upper normal serum value)
at any time on or after 3rd postoperative day. The issue was
however further compounded by the concept of “clinical
relevance”, a phrase often employed to distinguish asymp-
tomatic biochemical PF from those that are associated with
clinical illness, therapeutic intervention, or death [11]. The
ISGPF adopted and modiﬁed the deﬁnition based on clinical
impact on the patients hospital course and eventual outcome
and graded PF into grade (A, B, C) (Table 2)[ 3–6]. The
grading was based on 9 clinical criteria (patient’s condition,
use of speciﬁc treatment, ultrasound and or CT ﬁndings,
persistent drainage longer than 3 weeks, reoperation, and
death, signs of infection, sepsis, and readmissions [3–6].
However the applicability and utility of ISGPF deﬁnition
in allowing uniform comparison of ﬁstula rates have been
questioned by some workers [12]. Recently Strasberg et al.
proposed that intra-abdominal collection along with hem-
orrhage and peritonitis is also the result of pancreaticoanas-
tomotic failure (PAF) which includes the entire spectrum
of clinically relevant problem associated with the loss of
integrity of pancreaticoenterostomy [12]. They also sought
to categorise ﬁstula that occur after distal pancreatectomy
(DP) or segmental resection and enucleation, situations that
do not involve pancreaticoenterostomy and hence an entity
that is distinct from ﬁstula occurring after PD. These ﬁstulas
were termed as pancreatic occlusion failure (POF). POF
commonly runs a more benign course compared to PAF,
since enzyme activation does not occur in the absence of
pancreaticoenteric anastomosis [12].
3. Risk Factors for Pancreatic Anastomotic
Leakage after PD
Risk factors for pancreatic leakage include general patient-
related risk factors (age, gender, jaundice, and malnutrition),
disease-related risk factors (pancreatic pathology, pancreatic
texture, pancreatic duct size, pancreatic juice output), and
procedure related factors (operative time, resection type,
anastomotic technique, intraoperative blood loss) [1–9]. In
addition, surgeons experience has been shown to correlate
with pancreatic anastomotic leakage rate and in some re-
ported cases the prophylactic use of somatostatin [2–6].
4.PancreasandDisease-RelatedRiskFactors
The most widely recognized risk factors for pancreatic ﬁstula
are directly linked to state and disease of the pancreas and
or/periampullary region [3–9]. Principal among them is a
soft pancreatic parenchyma [3, 6]. In a series of nearly 2000
pancreaticoduodenectomies,itwasnotedthatasoftpancreas
was associated with a 22.6% ﬁstula rate and led to a 10-fold
increased risk of pancreatic ﬁstula versus an intermediate
or hard gland [13]. Other investigations have similarly
reported high rates of pancreatic ﬁstula in the presence of
soft pancreatic parenchyma [3–6, 14, 15]. In other reports,
while 25% of patients with soft pancreatic texture were
found to be complicated with pancreatic leak, none of the
patientswithhardpancreaticremnantsdevelopedpancreatic
leakage [14, 16]. It has been widely accepted that a ﬁbrotic
pancreatic remnant in patients with chronic pancreatitis
facilitates pancreaticoenteric anastomosis, whereas a soft and
friable pancreatic parenchyma makes the anastomosis diﬃ-
cult to perform [3–6]. Hence a strong association between
pancreatic texture and pancreatic leakage is found.
The size of the pancreatic duct has been implicated as a
major predictor of ﬁstula [14]. This is particularly so when
small nondilated pancreatic ducts, typically deﬁned as less
than or equal to 3mm in diameter, predispose patients to
pancreatic ﬁstulae, compared to 7% of patients with dilated
ducts [3, 5, 6]. Other disease-related risk factors include
resection of pathologic lesions like ampullary or duodenal
carcinoma, distal cholangiocarcinoma, intraductal papillary
mucinous neoplasia, pancreatic cystadenomas, benign islet
tumours,duodenaladenomas,andincreasedpancreaticjuice
output [13, 17].
5.Patient-RelatedRiskFactors
Patientcharacteristicshavealsobeenconsideredaspredictive
factors for pancreatic ﬁstula including male sex, advanced
age (>70 years), identiﬁable jaundice, creatinine clearance
abnormality, and intraoperative blood loss and coronary
arterydisease[2–9].Anumberofstudies,includingprospec-
tive,havefoundpatient’s agegreaterthan70yearsastheonly
factor associated with poor anastomotic healing leading to
pancreatic ﬁstula [13, 16]. A fourfold increased likelihood
has been found in patients with coronary artery disease,
in multivariate analysis [13]. This is likely to be related to
impairedanastomotichealingduetoimpairedvisceralperfu-
sion. Jaundice and creatinine clearance have been previously
reported to be patient-related risk factors, predisposing to
pancreatic ﬁstula after PD [13]. The duration of jaundice
rather than the extent of jaundice is found to inﬂuence this
poor outcome [18]. Yeh et al. demonstrated that the average
duration of jaundice among patients with pancreatic ﬁstula
was nearly twice as long as that among patients in no ﬁstula
group: 45 ± 21 days versus 23 ± 11 days (P = 0.018).
Serum bilirubin level had no signiﬁcant impact on ﬁstula
development in them [18]. The pancreatic ﬁstula was also
associated with a signiﬁcantly lower creatinine clearance:
59 ± 18mL/min versus 71 ± 14mL/min(P = 0.005 [18]).
The impaired creatinine clearance deﬁned as <50mL/minInternational Journal of Surgical Oncology 3
Table 2: Criteria for grading pancreatic ﬁstula (ISGPF classiﬁcation scheme). Signs of infection include elevated body temperature >38◦C,
leukocytosis and localized erythema, induration, or purulent discharge. Readmission is any hospital admission within 30 days following
hospital discharge from the initial operation. Sepsis is the presence of localized infection and positive culture with evidence of bacteraemia
(i.e., chills, rigors, elevated WBC) requiring IV antibiotic treatment, or hemodynamic compromise as demonstrated by high cardiac output
and low SVR within 24h of body temperature >38◦C.
Criteria No ﬁstula Grade A ﬁstula Grade B ﬁstula Grade C ﬁstula
Drain Amylase level <3 times normal serum
amylase
>3 times normal
serum amylase
>3 times normal serum
amylase
>3 times normal serum
amylase
Clinical conditions Well Well Often well Ill appearing
Speciﬁc treatment No No Yes/no Yes
US/CT if obtained Negative Negative Negative/positive positive
Persistent drainage
(>3w e e k s ) No No Usually yes Yes
Signs of infection No No Yes Yes
Readmission No No Yes/no Yes/no
Sepsis No No No Yes
Reoperation No No No Yes
Death related to ﬁstula no no no Yes
Adapted from [8].
precipitates acute renal failure, intra-abdominal bleeding,
and sepsis, processes that predispose patients to pancreatic
ﬁstula particularly in those with obstructive jaundice [18].
Interestingly diabetes mellitus and neoadjuvant chemoradi-
ation therapy have been shown to oﬀer a protective beneﬁt
against pancreatic ﬁstula, with the latter presumably causing
a decrease in pancreatic exocrine secretion [19, 20]
6.OperativeRisk Factors
In the past two decades, various technical aspects have
been scrutinized to identify operative factors associated with
increased ﬁstula rates [1–10]. Various techniques for man-
aging the pancreatic remnant have been compared including
pancreaticojejunostomy versus pancreaticogastrostomy, the
duct mucosa versus invagination pancreaticojejunal anasto-
mosis, stent versus no stent across the pancreaticoenteric
anastomosis, single versus double Roux-en-Y loop recon-
struction, and the use of somatostatin analogues and/or ﬁb-
rin sealants [1–10].
There are other factors apart from technical consider-
ation, of which increased intraoperative blood loss is an
important risk factor for developing PF. In one of the studies
pancreatic ﬁstula group suﬀered signiﬁcantly greater blood
loss,ratherthantheirnoﬁstulacounterparts:1584 ±862mL
versus 794 ± 387mL (P = 0.0005) [18]. The investigators
proposed that blood loss exceeding 1,500mL is at higher risk
of ﬁstula development. The increased blood loss is likely to
be associated with other factors including more advanced
stages of disease (i.e., portal or superior mesenteric vein
invasion, patient obesity, jaundice-associated coagulopathy
and concurrent pancreatitis [5, 6, 18]).
The risk factors of pancreatic ﬁstula were reported
following the analysis of the outcome in 233 consecutive
PD [18]. They were summarized as small pancreatic ducts
less than or equal to 3mm in diameter; soft pancreatic
parenchyma; ampullary, duodenal, cystic, or islet cell pathol-
ogy; and intraoperative blood loss greater than 1000mL; all
of them were associated with an increased risk of developing
a clinically relevant pancreatic ﬁstulae (grades B and C) [18].
No veriﬁable risk factors for biochemical grade A ﬁstulae
were found in this study [18]. PF leads to delay in surgical
recovery, and prolongs hospital stay and the related increase
in substantial increase in hospital costs [3–8, 18, 21].
Risk factors for pancreatic ﬁstula following distal pan-
createctomy are poorly understood. Factors that have been
implicated include body mass index greater than 25kg/m2,
transectionsatthepancreaticbodyandabsenceofpancreatic
duct ligation [22, 23]. In a study of 64 patients with
distal pancreatectomy, 29% developed grade A ﬁstula, 64%
developed grade B, and 7% developed grade C, PF [24]. The
risk factors associated with signiﬁcantly higher rate of PF in
this series were reported to be soft pancreatic tissue, spleen
preserving procedures, and the nonuse of postoperative
prophylactic octreotide [24]. Age, gender, and technique of
pancreatic stump closure in this analysis were not associated
with ﬁstula development [24].
7.ClinicalCourse
The consequence of PF is increased risk of morbidity, mor-
tality, and longer hospital stay and cost. Among the number
of series recently published, the reported incidence of PF
following pancreaticoduodenectomy ranged from 6% to
14% and the reported mortality from 1.4% to 3.7% [1–13].
In addition, PF is associated with other nonﬁstulous compli-
cations, particularly delayed gastric emptying, ileus, wound
infection, intra-abdominal abscess, pancreatitis, haemor-
rhage, and sepsis. The hospital costs and rate of reoperation
and hospital readmission are signiﬁcantly increased [3–8].4 International Journal of Surgical Oncology
The highest rate of PF however follows central pancrea-
tectomy, which ranges from 20% to 63% among specialized
center [25], in contrast to 5% following distal pancre-
atectomy [26]. The higher rates of PF following central
pancreatectomy are presumed to be due to the creation of
two pancreatic remnants in this procedure and thus two
potential sites for ﬁstula formation [25]. A study comparing
theclinicalandeconomiceﬀectsofpancreaticﬁstulaeamong
patients undergoing pancreaticoduodenectomy revealed that
the incidence of clinically relevant ﬁstulae (grades B and
C, according to ISGPF grading system) was 16% for pan-
creaticoduodenectomy, 13% for distal pancreatectomy, and
83% for central pancreatectomy [27]. Moreover it also
revealed the impact of increasing risk factors on the risk
of developing PF. The rate of PF in this study was 2%,
8%, 16%, 31%, and 100% in patients with number of risk
factors, 0, 1, 2, 3, and 4 respectively [27]. The clinical
course of these ﬁstulas depended on the type of resection
performed.PFfollowingpancreaticoduodenectomyandcen-
tral pancreatectomy led to acute manifestation and often
required aggressive management in intensive care setting
[2–6]. Surgical exploration when indicated was urgent and
usually occurred early in the postoperative period. On the
contrary patients after distal pancreatectomy seldom re-
quired aggressive management approaches nor experienced
prolonged hospital stay. Unlike patients with leak post
pancreaticoduodenectomy, these patients were typically dis-
charged home rather than to rehabilitation facilities [27].
Prolonged drainage of intra-abdominal collections of more
than 3 weeks and multiple hospital readmissions (usually
for image-guided percutaneous) are more likely following
leaks related after PD [1–8]. In a critical review of 232 cases
of distal pancreatectomy, the pancreatic ﬁstula was reported
in 31% of patients (grade A = 18%, grade B = 6%, and
grade C = 8%). The predominant factors associated with
the leak were increased weight, higher American Society of
Anesthesiologistsscore,bloodlossgreaterthan1L,increased
operation time, decreased albumin level, and sutured closure
of the stump without the main duct ligation. A DP with
splenectomy was associated with a higher incidence of grade
B or C PF. Importantly ninety-two percent of PF was suc-
cessfully managed nonoperatively [28].
8. PreventiveApproaches
8.1. Technical Intervention. To prevent complications fol-
lowing PD, various techniques of managing the pancreatic
remnant have been proposed. These range from pancreatic
ductal occlusion to pancreaticoenterostomy with jejunum or
stomach [1–12].
8.2. Pancreatic Duct Occlusion. In an attempt to obviate a
pancreatiocenteric anastomosis, pancreatic ductal occlusion
was studied [28, 29]. Occlusion of the pancreatic duct can be
achieved by simple suture ligation of the duct or injection of
the duct with nonreabsorbable or reabsorbable glues [3–6].
In a study comparing pancreatic ductal occlusion by primary
closure of the pancreatic duct, oversewing of the pancreatic
stump and external drainage with pancreaticojejunostomy,
the ﬁndings noted were that the ductal occlusion group
had lower morbidity (56% versus 24%), decreased mortality
(11% versus 0%), and shorter hospital stay (42.2 versus 26.4
days) [29]. However the number of cases was smaller. In
another study with a slightly larger group of patients, where
86 patients received chemical and suture occlusion of the
pancreatic duct compared with 83 patients with pancre-
aticojejunostomy, there was no signiﬁcant diﬀerence found
in the postoperative complication, mortality, and exocrine
insuﬃciency [30]. The pancreatic ﬁstula rate was signiﬁ-
cantly higher in the ductal occlusion group (17% versus
5%). After 3 and 12 months, there were signiﬁcantly more
patients with diabetes mellitus in the ductal occlusion group
[30]. So far insuﬃcient evidence exists to show that pan-
creaticoenterostomy can be replaced by pancreatic ductal
occlusion.
8.3. Pancreaticogastrostomy. W a u g ha n dC l a g e t tﬁ r s tp e r -
formed pancreaticogastrostomy (PG) in clinical practice in
1946 [31]. PG has gained favour in recent years as a possible
means of reducing the incidence of pancreatic ﬁstula [31–
39]. Proponents have noticed several potential advantages.
These include that pancreatic enzymes are inactivated by
gastric acid environment; moreover the enzymes remain in
inactive form as stomach does not contain enterokinase,
which is required for conversion of trypsinogen to trypsin
and subsequent activation of proteolytic enzymes. A lack
of enzyme activation may help prevent autodigestion of the
anastomosis. Furthermore the proximity of the pancreas to
the posterior stomach wall allows potentially less tension on
the anastomosis. The excellent blood supply to the stomach
wall is favourable to anastomotic healing and the thickness
of the stomach holds sutures well.
There are 3 RCTs comparing pancreaticogastrostomy
[32, 36, 37]. They failed to show any signiﬁcant diﬀerence
regarding pancreatic ﬁstula rates, postoperative complica-
tions, and mortality. Two meta-analyses that have been
published recently attempted to resolve this controversy
[38, 39]. In an analysis of 11 articles along with 1 RCT, 2
prospective nonrandomized trials, and 8 cohort studies, the
ﬁndings suggested that PG was safer after PD, but much of
the evidence came from cohort studies [38]. The study of
Wente et al. analyzed 16 articles including 3 RCTs [39]. The
results indicated that all cohort studies reported superiority
of PG most likely inﬂuenced by publication bias [39]. In
contrast, all RCTs failed to show an advantage of a particular
techniquesuggestingthatbothtechniqueswereequallygood.
Based on the current evidence, PG and PJ are equivalent in
t e r m so fp e r i o p e r a t i v eo u t c o m e( e v i d e n c el e v e l s1 ,a n d2 ) .
8.4. Pancreaticojejunostomy. Pancreaticojejunostomy has been
the most commonly used method of pancreaticoenteric
anastomosis after PD [1–12]. This method reestablishes
enteric ﬂow of pancreatic juice after pancreaticoduodenec-
tomy by uniting the remnant pancreatic tissue with a loop
of jejunum. The jejunum is a logical choice for a pancreati-
coenteric anastomosis due to its generous blood supply andInternational Journal of Surgical Oncology 5
mobilemesentery.Yetduringthepast30years,thistechnique
has consistently been reported to yield on an average a
10% ﬁstula rate (range 2 to 19%) [40]. Apart from the
diﬀerent positions of the jejunal loop (antecolic, retrocolic,
or retromesenteric) and other variations, such as isolated
Roux loop PJ, the anastomosis can be performed as an end-
to-end anastomosis with invagination of the pancreatic
stump in the jejunum or as end to side anastomosis with
or without duct to mucosa suturing [40]. In addition to
these, there are some more variations of these anastomotic
techniques.
Duct to mucosa pancreaticojejunal anastomosis allows
direct contact of the pancreatic duct with jejunal mucosa,
preventing direct contact of the pancreatic juice with the
cut end of the pancreas and thus helping healing of the
mucosa and protecting the anastomosis by embedding the
pancreatic remnant under jejunal serosa [3–6, 17, 41].
Therefore,duct-to-mucosaanastomosisistheoreticallymore
rational technique to avoid pancreatic ﬁstulae. Since it is
technically diﬃcult to perform, duct to mucosa pancre-
aticojejunal anastomosis was previously recommended for
patients with dilated pancreatic duct, whereas in recent
years this technique has been preferred regardless of the
diameter of the pancreatic duct [5, 6, 41]. Reviewing various
techniques in the literatures published over the last decade,
Poon et al., found that the duct-to-mucosa anastomosis was
safer technique than invagination anastomosis [17].
Marcus et al., found that duct-to-mucosa anastomosis
was associated with a low pancreatic ﬁstula rate in low-risk
patients with a dilated pancreatic duct or a ﬁbrotic pancreas,
whereas end-to-end invagination technique was a safer in
high-risk patients with small ducts or a soft friable pancreas
[42]. Suzuki et al. selected various pancreaticojejunostomy
techniques according to the pancreatic texture and duct
size and obtained an overall pancreatic leakage rate of 8%
(4/50) [43]. The patients who developed pancreatic ﬁstulae
were all with a small duct and a soft pancreas. In that
series, the incidence of pancreatic leakage rate was 6.25% in
patientswhounderwentaducttomucosapancreaticojejunal
anastomosis compared to 19.6% in invagination group [43].
However a prospective RCT by Bassi et al. revealed no
signiﬁcant diﬀerence in the morbidity and PF rate between
duct to mucosa anastomosis and single-layer end-to-side
pancreaticojejunostomy [44].
8.5. Isolated Roux Loop Pancreaticojejunostomy. Separation
of the pancreaticojejunal and hepatojejunal anastomosis by
an isolated Roux loop reconstruction was advocated to
minimize the incidence and severity of anastomotic erosion
by pancreatic juice activated by bile [45, 46]. Potential dis-
advantages are increased operating time and the need for an
additional anastomosis. Several cohort studies have reported
a low pancreatic ﬁstula rate and its related mortality [45, 46].
In the only nonrandomized study, by Kaman et al., the data
failed to show any signiﬁcant diﬀerence in the pancreatic
ﬁstularates(10%versus12)followingtheisolatedRouxloop
pancreaticojejunal reconstruction or conventional single
loop pancreaticojejunal reconstruction after PD [47]. Based
on the limited evidence, the use of isolated Roux loop pan-
creaticojejunostomy cannot prevent pancreatic ﬁstula for-
m a t i o n( e v i d e n c el e v e l s3 b ,a n d4 )[ 6].
9.Other SurgicalTechnical
Modiﬁcations/Approaches
9.1. Role of Magniﬁcation in Pancreatic Anastomosis. Since a
duct-to-mucosa anastomosis is crucial for good outcome, a
meticulous approximation assumes great importance. Oper-
ating loupes have been used by many experts to allow precise
reconstruction of pancreatic anastomosis [48]. Technical
errorsthatmayoccurduringanastomosisincludecrossingof
the sutures, including both sides of the pancreatic duct while
passingthesutures,takingunequalorinadequateamountsof
pancreaticductandjejunalmucosaandincorrectknotplace-
mentresultinginairknots.Alltheseeventscanbeavoidedby
using magniﬁcation. Some have reported markedly reduced
incidence of PF with the operating microscope compared to
operating loupes [48].
9.2. Blood-Supply-Based Technique of PD. One of the few
modiﬁcations which have demonstrated a substantial reduc-
tion in the rate of PF after PD was proposed by Strasberg et
al. [49]. A concept of vascular watershed in the pancreatic
neck and its role in ischaemia of the cut surface of pancreatic
remnant has been proposed by them. Based on this concept,
the blood supply at the cut surface of the pancreas is
evaluated in the techniques and if necessary the pancreas
is cut back 1.5cm to 2cm to improve the blood supply
(n = 47, 38%) [49]. Thereafter the anastomosis is performed
meticulously under magniﬁcation.
9.3. Total Pancreatectomy. The rational for total pancreate-
c t o m yi st h a ti ta l l o w sam o r ee x t e n s i v el y m p h a d e n e c t o m y ,
obviates the risk of a leak from the pancreatic anastomosis
and decreases the chance of a positive resection margin.
However total pancreatectomy is associated with obligatory
diabetes mellitus, decreased immunity because of splenec-
tomy, and loss of pancreatic exocrine function [50, 51].
Hence it is no surprise that most studies have reported
either worse survival or no survival diﬀerence between total
pancreatectomyandstandardPD[50,51].Theindicationfor
total pancreatectomy would include serial positive resection
margin obtained on frozen section, a very soft pancreas
with a potentially increased risk of PF and in patients with
documented family history of multicentric disease [50, 51].
9.4. Pancreatic Duct Stenting. One of the technical modi-
ﬁcations in pancreaticoenteric anastomosis is the use of a
transanastomotic stent for internal and external drainage of
pancreatic secretion [52–57]. The potential advantages of
a pancreatic stent include diversion of pancreatic secretion
from the anastomosis and facilitation for more precise place-
ment of sutures during the anastomosis, thus protecting the
pancreatic duct from suture injury and reducing the risk of
iatrogenicpancreaticductocclusion.Howevercomplications
such as obstruction of the stent leading to pancreatic ﬁstula6 International Journal of Surgical Oncology
and migration of the stent are drawbacks with transanasto-
moticstenting. Thenumberofstudiesonpancreaticstenting
is limited and the results are conﬂicting [52–57].
Internal transanastomotic stenting was reported to re-
duce the pancreatic ﬁstula of pancreaticojejunal anastomosis
in cohort study [52]. However in the nonrandomized study
by Imaizumi et al. with 168 patients, there was no signiﬁcant
diﬀerence in the pancreatic ﬁstula rates between end-to-
side pancreaticojejunostomy of normal soft pancreas using
stented (internal or external) method versus non stented
methods (5.7% versus 6.7%) [54]. The internal pancreatic
stent was evaluated by Winter et al. in an RT among 234
patients [55].The study showed that internal pancreatic duct
stenting did not decrease the frequency or the severity of the
postoperative ﬁstulas. The pancreatic ﬁstula rates in patients
undergoing PD with or without an internal pancreatic stent
were 11.3 and 7.6%, respectively [55].
An external stent has a theoretical advantage of more
complete diversion of pancreatic secretion away from the
pancreaticojejunal anastomosis and prevents the activation
of pancreatic enzyme by bile [56]. The nonrandomized
study by Ohwada et al. showed equivalent outcomes for
external and internal pancreatic stenting of duct-to-mucosa
pancreaticojejunostomy after PD [56]. However the RCT by
Poon et al. showed that among the 120 patients who were
externally stented, pancreatic ﬁstula rate was signiﬁcantly
lower in them compared to the nonstented group (6.7%
versus 20%) [57] .Ar e c e n ts t u d yo f1 5 8p a t i e n t sw h o
underwent PD and were randomized to receive an external
stent or no stent revealed that the stented group had a
signiﬁcantly lower rate of pancreatic ﬁstula (26% versus
42%), P = 0.034., morbidity (41.5% versus 61.7%), P =
0.01, and delayed gastric emptying (7.8% versus 27.2%)
P = 0.001 [58]. Based on the current evidence, it is unclear
whether drainage of the pancreatic duct with a stent can
reduce the pancreatic ﬁstula rate after PD (evidence levels 2
and3b).Henceaninternalandexternalpancreaticductstent
may or may not be placed across these anastomosis. Though
some of the evidence shows that external stenting technique
issuperior,itappearsthataslongastension-freeanastomosis
between well-perfused tissues is performed, employing ﬁne
sutures and using the same technique, any type of pancreatic
anastomosis should result in a good outcome.
9.5. Pharmacologic Intervention. Somatostatin is a potent
inhibitor of endocrine and exocrine functions. The synthetic
peptide octreotide contains the same amino acid sequences
essential to the activity of somatostatin, while conferring
resistance to enzyme degradation, resulting in a long acting
stable analog suitable for subcutaneous administration. The
rationale of its use following PD is that by decreasing the
volume of pancreatic secretion, the pancreatic ﬁstula rate
would be decreased because of which the pancreaticoenteric
anastomosis would heal better. Adverse eﬀects of somato-
statin and its analogues include nausea, ﬂatulence, diarrhea,
steatorrhea, pain at the injection site, and abdominal dis-
comfort. There are 11 RCTs involving 2023 patients in whom
the somatostatin analogue was examined [59–69]. Five RCTs
from Europe [59–69] and 1 RCT from Asia [65] showed
the beneﬁt of perioperative use of somatostatin analogues to
decrease the postoperative complication rate. On the other
hand, 2 recent RCTs from Europe [66, 67] and 3 RCTs
from USA tates failed to show beneﬁt [11, 15, 64]. Two
recent meta-analyses have been published. Connor et al.
analyzed 10 studies and showed that somatostatin and its
analogues reduced rate of biochemical ﬁstula but not the
incidence of clinical anastomotic disruption [68]. In another
report involving seven studies, the perioperative octreotide
administration was associated with signiﬁcant reduction of
pancreatic ﬁstula rate after pancreatic surgery [69]. However
the risk reduction was not associated with a signiﬁcant
diﬀerence in postoperative mortality. Conclusions drawn
from these meta-analysis should be cautionary, as pooling
of data from these RCTs was diﬃcult because there was
considerable heterogenicity in these studies from end point
measures, deﬁnition of outcome measurements, treatment
regimens, pathologic ﬁndings, type of pancreatic surgery,
and anastomotic technique.
Hence the prophylactic use of perioperative somatostatin
and its analogues to prevent pancreas-related complications
after pancreatic surgery remains controversial. It does not
result in a reduction of mortality. However the eﬃcacy
of prophylactic octreotide is reported to be improved, by
selective administration in the setting of high risk glands,
including patients with either soft glands or small pancreatic
duct, in those harbouring ampullary, duodenal cystic or islet
lesions, or in case where intraoperative blood loss is excessive
[3]. Prophylactic octreotide did not inﬂuence clinically
relevant ﬁstula rates among low-risk glands [3] .T h e r ei sa
need for RCTs with standardization in deﬁnition of outcome
measurements, treatment regimen, surgical technique, and
stratiﬁcation of risk factors.
10. Management Approaches
In recent years, pancreatic surgeons have strived hard to
reduce postoperative PF by developing numerous novel
strategies [1–13]. But the cornerstone of minimizing the
potentially devastating eﬀect of PF is to recognize this
complication as soon as it develops and to institute appro-
priate treatment measures promptly [2–8]. The suspicion
of PF begins whenever there is a deviation in the normal
clinical course of a patient who has just undergone a major
pancreatic surgery. This includes a patient who develops
unexpected upper abdominal discomfort (often associated
with fever), leukocytosis, increasing tachycardia, or just feels
unwell after an apparently “normal” initial postoperative
recovery [3, 5, 6]. This suspicion may be substantiated by the
presence of high amylase content of the drain, a persistently
highdrainoutput,altereddraincolourandquality,andother
complications such as severe wound infection and haem-
orrhage. Routine radiological investigation is generally not
recommendedasitisnotnecessary[3,6].Oncethediagnosis
of PF is established, aggressive and appropriate conservative
management is the key to successful outcome in majority
of the patients [2–12]. However, interventional radiologicalInternational Journal of Surgical Oncology 7
assistance is sometimes required, but repeat surgery is rarely
indicated [3, 7, 35].
11. Conservative Management
Nonoperative management of pancreatic ﬁstula includes
treatment for postoperative ileus and intra-abdominal col-
lection and is successful in about 90% of cases [70, 71].
Clinical evaluation of the patient at short intervals is of
outmost importance. Patients are kept nil per oral and
provided adequate hydration. In those patients who have
not yet tolerated oral or those who are presenting with
complication on or after the 10th postoperative day, would
require parenteral nutritional support [3–6]. Nutrition
can also be maintained by enteral nutrition (through an
operatively placed nasojejunal tube or feeding jejunostomy)
in less severe cases. Empiric antibiotics are given if signs
of infection (i.e., fever, leukocytosis, purulent discharge,
erythema, warmth, tenderness) are present and adjusted
depending on information from gram stains or cultures.
Intra-abdominal drains are left in situ until daily drainage
volumes approach 50mL per day; patients can be discharged
home as long the character of the drainage is not purulent
or particulate. Cautious drain management (i.e., in situ
drainage is indicated in patients with high-output drainage
(greater than 200mL per day) and amylase rich eﬄuent
(greater than 1000IU/L) [2–6]). Therapeutic octreotide may
be administered to reduce pancreatic secretions, typically
until oral intake resumes and/or hospital discharge occurs.
All along abdominal drains and the main wound would
require close attention [3–6].
The interventional radiologist may play a crucial role
by image-guided repositioning of operatively placed drains
and insertion of percutaneous catheters to drain collections
seen in CT scan [71, 72]. Delayed haemorrhage following
PF is a major concern and is probably best managed by
angiographyandembolizationofthebleedingvessel[73,74].
This treatment is successful in stopping the bleeding in
80% of patients [73, 74]. The prognosis of patients with
postpancreatectomy haemorrhage depends on whether or
not PF is present. The decision-making should be guided by
factors such as the time of onset of the bleeding, presence
of PF, vascular pathology, and the underlying disease process
[73, 74]. The failure to successfully control haemorrhage by
conservative measures like angiographic embolization may
necessitate repeat surgery [73, 74].
Intra-abdominal collection can be dealt by CT or ul-
trasound-guided percutaneous drainage and is considered
at the discretion of the surgeon (Figure 1). Some employ
this modality in the presence of large ﬂuid collections that
have not responded to conservative therapies, but which are
amenable to drainage [2–6, 13]. Surgical exploration is sel-
dom required but is indicated when anastomotic dehiscence
is suspected and for patients who deteriorate clinically often
in the setting of a non drainable abscess, sepsis, or multiple-
organ dysfunction. The options that are considered include
wide peripancreatic drainage of an abscess or ﬂuid collec-
tion, revision of the initial pancreaticoenteric anastomosis,
Figure 1: CT scan carried out on the 9th postoperative day follow-
ing pancreaticoduodenectomy reveal peripancreaticojejunal anas-
tomosis collection (straight arrows). This grade B pancreatic ﬁstula
was successfully managed by CT guided aspiration. The internal
pancreatic duct stent is also seen (curved arrows).
conversion to an alternative pancreaticoenteric anastomosis,
or completion pancreatectomy (i.e., total pancreatectomy).
Surgical peripancreatic drainage, which is proposed as a
safer alternative, to completion pancreatectomy, may be suit-
able for less severe postoperative pancreatic ﬁstula. However
in patients with severe postoperative pancreatic ﬁstula with
disruption of the pancreaticojejunostomy, simple peripan-
creatic drainage might not be eﬀective [14, 75]. Completion
pancreatectomy,whichisoftenusedasasalvageprocedurein
such instance, however is associated with high perioperative
mortality ranging from 75% to 100% with severe morbidity
of brittle diabetes [14, 75, 76]. The associated morbidity of
type 1 diabetes and exocrine insuﬃciency constitute lifelong
morbidity requiring frequent hospitalization. Hence to avoid
these complications, some have recommended salvage pan-
creaticogastrostomy [75]. The relatively favourable outcome
following this procedure is attributable to the anatomic
positionofthepancreas,whichmakesPGrelativelyeasyeven
in the presence of pancreatitis or peritonitis, in addition to
failure of activation of enzyme in the absence of enterokinase
in the stomach and feasibility of drainage pancreatic juice by
continuous gastric aspiration [75].
12. Conclusions
Pancreatic resection is now considered a safe procedure,
when performed in high-volume centers. It is associated
with low mortality rates, shorter hospital stays, and modest
improvements in postoperative morbidity. PF from pancre-
aticoenteric anastomosis, however, continues to be a sig-
niﬁcant problem after PD.
The deﬁnition and grading system put forth by the inter-
national study group on PF is now standard consensus
deﬁnition for PF and helps in comparing results of various8 International Journal of Surgical Oncology
reports. Among the numerous risk factors for the clini-
cally relevant ﬁstula, the most likely are soft pancreatic
parenchyma, small pancreatic ducts, resection for ampullary,
duodenal, cystic and islet cell pathology, and excessive blood
loss. Preventive approaches to reduce the rate of PF include
technical and anastomotic modiﬁcations, particularly the
employmentofduct-to-mucosaanastomosis.Useofprophy-
lactic octreotide is found to be beneﬁcial in select group of
patients, like those at high risk for developing PF. Successful
management of this serious complication depends on early
detection, which requires a high index of clinical suspicion.
Analysis of drainage ﬂuid is the principal diagnostic tool, but
computed tomography, ultrasound, and pancreaticography
provide additional information. Nonoperative management
strategies form the cornerstone of management in majority
of the patients and include managing ﬂuid balance, pro-
viding parenteral nutritional support and administrating
antibiotics or octreotide. Image-guided drainage or surgical
exploration is indicated if large ﬂuid collections persist
and/or patients deteriorate clinically. The indication for
surgical intervention in PF includes worsening clinical pa-
rameters, signs of spreading peritonitis, severe wound infec-
tion, wound dehiscence, and disruption of pancreatic anas-
tomosis. The surgical intervention may be of minimal
nature by draining the peripancreatic ﬂuid or involve salvage
completion pancreatectomy.
In spite of long standing experience with PF, pancreatic
surgeons continue to invest signiﬁcant eﬀort to improve
perioperative management of this complication. As current
ﬁstula rates hover around 15%, the future success of pancre-
atic surgery will require better diagnostic approaches, novel
management algorithms, randomized clinical trials, multi-
institutional investigations, and multidisciplinary collabora-
tion in order to reach negligible level of PF.
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